Postby Rock_Robster » Mon Apr 22, 2019 2:16 am
For response rates, it’s a tricky question to answer, but Table 7 in the below provides an overview from a range of studies. There’s a few complicating factors, including what counts as a response (stable disease? Shrinkage?), and inclusion of targeted therapies (Bevacizumab, cetuximab). As a rough figure though I think you’d be reasonable to take a number in the order of about 60% (possibly higher if you include stable disease, and/or targeted therapies).
https://onlinelibrary.wiley.com/doi/ful ... ags3.12071This study showed a wide range of response rates of 40% and almost 80%, again depending on measurement criteria used:
https://www.ajronline.org/doi/10.2214/AJR.11.7910My situation was similar to yours - I was lucky to be resectable at diagnosis but still did 6 rounds of FOLFOX before liver resection; scans before surgery had good shrinkage, and pathology after surgery showed tumour necrosis ranging 40-80%.
I was also told that CEA taken during chemo is not particularly meaningful.
Best of luck.
41M Australia
2018 Dx RC
G2 EMVI LVI, 4 liver mets
pT3N1aM1a Stage IVa MSS NRAS G13R
CEA 14>2>32>16>19>30>140>70
11/18 FOLFOX
3/19 Liver resection
5/19 Pelvic IMRT
7/19 ULAR
8/19 Liver met
8/19 FOLFOX, FOLFOXIRI, FOLFIRI
12/19 Liver resection
NED 2 years
11/21 Liver met, PALN, lung nodules
3/22 PVE, lymphadenectomy, liver SBRT
10/22 PALN SBRT
11/22 Liver mets, peri nodule. Xeloda+Bev
4/23 XELIRI+Bev
9/23 ATRIUM trial
12/23 Modified FOLFIRI+Bev
3/24 VAXINIA (CF33 + hNIS) trial